Skip to content

Oruka Therapeutics, Inc. ORKA Marketable Securities

Marketable Securities at other companies

General Dynamics logo
General DynamicsGD
$207M-1.0%
KLA Corporation logo
KLA CorporationKLAC
$3.17B+46.1%
DexCom logo
DexComDXCM
$1.3B
Citigroup logo
CitigroupC
$6.29B+9.7%
FB Financial logo
FB FinancialFBK
$79.46M
Wintrust Financial logo
Wintrust FinancialWTFC
$9.4B+34.3%

Other financials

Income statement

See full
Revenue-
Operating income-$36.4M-45.2%
Net income-$31.8M-51.5%
EPS (diluted)-$0.46+93.4%

Balance sheet

See full
Cash & equivalents$49.5M-40.7%
Total debt$1.8M+90.8%
Total equity$486.7M+33.4%
Total assets$504.5M+33.8%

Cash flow

See full
Operating cash flow-$23.6M-13.0%
CapEx$73.0K+462%
Free cash flow-$23.7M-13.3%

Valuation

See full
Market cap$5.03B+533%

Returns & leverage

See full
Return on equity-27.3%-11.1pp
Debt / equity0.0×
Current ratio23.8×-6.3×

Where this comes from

Reported directly by Oruka Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:MarketableSecurities.

The official record: Oruka Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Oruka Therapeutics, Inc.'s marketable securities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Oruka Therapeutics, Inc.'s marketable securities?
Oruka Therapeutics, Inc. (ORKA) reported marketable securities of $446.43M in Q1 2026.
How has Oruka Therapeutics, Inc.'s marketable securities changed year-over-year?
Oruka Therapeutics, Inc.'s marketable securities increased by 54.2% year-over-year, from $289.48M to $446.43M.